血小板高反应性的遗传因素及其药物治疗策略的研究进展
Research progress on genetic factors of high on-treatment platelet reactivity and its drug treatment strategies
张峰森 1王芳 1甄媛媛 1夏一淼 1李晶 1何春远 1袁宏中 1王法财1
作者信息
- 1. 六安市人民医院 安徽医科大学附属六安医院,安徽 六安 237005
- 折叠
摘要
抗血小板药物是目前治疗缺血性心脏病的常用药物,主要包括氯吡格雷、阿司匹林,但易发生氯吡格雷抵抗、阿司匹林抵抗,而它们同属于抗凝治疗后血小板高反应性的范畴.遗传因素对血小板高反应性的影响至关重要.目前对血小板高反应性的治疗策略主要以个体化抗血小板治疗为主,常用的药物包括替格瑞洛、αIIbβ3 拮抗剂、中药.总结了血小板高反应性的遗传因素和治疗策略的研究进展,旨在为血小板高反应性的治疗提供临床参考.
Abstract
Antiplatelet drugs are currently commonly used in the treatment of ischemic heart disease,mainly including clopidogrel and aspirin.However,they are easy to develop clopidogrel resistance and aspirin resistance,both of which belong to high on-treatment platelet reactivity after anticoagulation therapy.The influence of genetic factors on high on-treatment platelet reactivity is crucial.At present,personalized antiplatelet therapy is the main treatment strategy for high on-treatment platelet reactivity,and commonly used drugs include ticagrelor,αIIbβ3 antagonists,and traditional Chinese medicine.This article summarizes the research progress on genetic factors and treatment strategies of high on-treatment platelet reactivity,to provide clinical reference for the treatment of high on-treatment platelet reactivity.
关键词
氯吡格雷/阿司匹林/血小板高反应性/遗传因素/抗血小板治疗Key words
clopidogrel/aspirin/high on-treatment platelet reactivity/genetic factor/antiplatelet therapy引用本文复制引用
基金项目
安徽省高等学校自然科学研究项目(KJ2021A0342)
安徽医科大学科研项目(2022xkj100)
六安市科技计划(2022lakj034)
出版年
2024
NETL
NSTL
万方数据